Clinical Trial: Phase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Pembrolizumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in Children

U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07020052) titled 'Phase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Pembrolizumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in Children' on June 05.

Brief Summary: This study is a phase II single center exploratory clinical trial aimed at evaluating the efficacy and safety of temozolomide combined with anlotinib synchronous radiotherapy sequential triple therapy (temozolomide/anlotinib/PD-L1 inhibitor) for the maintenance treatment of diffuse midline gliomas (DMG) in children. The research plan includes 33 children with DMG aged 3...